Clinical Practice Guideline for the Appropriate Use of Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder
Monash University's Centre for Medicine Use and Safety (CMUS) and Neuromedicines Discovery Centre (NDC) have led a multidisciplinary project to develop the Clinical Practice Guideline for the Appropriate Use of Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder (the Guideline).
The Guideline has been developed to support clinicians and people living with post-traumatic stress disorder (PTSD) to make informed decisions about Methylenedioxymethamphetamine-Assisted Psychotherapy (MDMA-AP). The Guidelines include four recommendations, 21 Good Practice Statements and 15 research recommendations. The Guideline is mainly intended for clinicians, including general practitioners, nurses, pharmacists, psychiatrists, psychologists, therapists, and other medical/allied health professionals involved in the management of PTSD. A Companion Guide has been developed to support people living with PTSD, their families and carers.
The Guideline Development Group developed recommendations and good practice statements based on systematic evidence review of published literature and consideration of benefits and harms, certainty of the evidence, consumer values and preferences, resources, equity, accessibility and feasibility.
The Guideline addresses the rapidly emerging field of MDMA-assisted therapy, where clinical uncertainty exists regarding what constitutes best practice, and there are heightened risks of misinformation or disinformation among consumers.
The Guideline was supported by philanthropic funding to the Neuromedicines Discovery Centre, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University. Funding to develop the Guideline was also provided by Monash University, the University of Melbourne, and The Florey Institute of Neuroscience and Mental Health. The philanthropic donor had no role in the design, data collection and analysis, decision to publish, or preparation of the Guideline.
Supporting Materials to Implement the Guidelines
The Guidelines can be accessed:
Clinical Practice Guideline for the Appropriate Use of Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder - Online via MAGICapp
The Companion Guide is for anyone who is impacted by post-traumatic stress disorder (PTSD). This includes people living with PTSD, their families and carers. The Companion Guide is also for the wider public. Health and care professionals may find the Companion Guide useful for shared decision-making.
Companion Guide - English